ESMO Breast Cancer Meeting


GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.

Visit us at booth No 20 and visit our presentations.

SASCIA - Oral presentation #58O
Date: Wed, 04.05.2022. Lecture time: 16:45
Session: Proffered Paper session 2
Chairs: G. Curigliano S. Delaloge S. Kim
Speakers: F. Marmé
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
F. Marmé, C. Hanusch, J. Furlanetto, et al.

PenelopeB - Mini oral #60MO
Date: Tue, 03.05.2022. Lecture time: 16:22 - 16:29
Session: Mini Oral session 1
Chairs: L. Del Mastro P. Poortmans
Speakers: J. Furlanetto
Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B
J. Furlanetto, F. Marmé, C. Thode, et al.

BMBC - Poster #170P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: K. Riecke
Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry
K. Riecke, E. Laakmann, T. Neunhöffer, et al.

GeparX - Poster #94P
Date: Wed, 04.05.2022. Lecture Time: 12:15 - 13:00
Speakers: M. Reinisch
Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)
M. Reinisch, J.-U. Blohmer, T. Link, et al.

GeparQuattro, GeparQuinto and GeparSixto - Poster #24P
Date: Wed, 04.05.2022
Lecture Time: 12:15 - 13:00
Speakers: B. Sinn
Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome
B. Sinn, M. Untch, T. Karn, et al.

ESMO Breast Cancer 3.-5. May 2022


  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd